Thank you very much for visiting our website. We are a very different pharmaceutical company. Our mission is to provide innovative products which satisfy real needs while ensuring maximum safety for everyone's' benefit.

+9122-3060-1000
+9122-2637-4592

Products in Development

In neurology, Taj Life Sciences, in collaboration with Wyeth, initiated a Phase II clinical trial for an experimental humanized monoclonal antibody with a targeted indication of immunotherapeutic treatment of mild to moderate Alzheimer’s disease (AD). The humanized monoclonal antibody is designed and engineered to clear the neurotoxic beta-amyloid peptide that accumulates in the brains of patients with AD.

In autoimmune diseases, Taj Life Sciences’s primary emphasis is studying and developing ways to provide disease-modifying therapies for a wide range of diseases.


* Business model and strategy
* Drug Technologies
* Discovery Research Projects
* Products in Development>>
* Business Development
* THE NEXT DIMENSION COMPANY

Life Sciences Goals

* Clinical Development
* Commercial Compliance
* Human Capital Management
* Operational Excellence
* Quality Systems
* Regulatory Planning & Remediation

2008 © Taj Life Sciences  Pvt. Ltd.
All rights Reserved. Read | Privacy Policy | Terms & Conditions | Sitemap